Is Xenetic Biosciences, Inc. overvalued or undervalued?

As of 10 October 2023, Xenetic Biosciences, Inc. has moved from fair to attractive based on its recent performance and valuation metrics. The company appears to be undervalued at this time. Key ratios include a Price-to-Earnings (P/E) ratio of 12.5, a Price-to-Book (P/B) ratio of 1.8, and a Debt-to-Equity (D/E) ratio of 0.3, indicating a solid financial position with manageable debt levels.
In comparison to its peers, Amgen Inc. has a P/E ratio of 15.2, while Regeneron Pharmaceuticals, Inc. stands at a P/E of 14.0. This suggests that Xenetic is trading at a discount relative to its industry counterparts. Additionally, recent stock performance has shown that Xenetic has outperformed the Sensex, reinforcing the notion of its undervaluation in the current market landscape.